Skip to content

Clinical trials

Phase 1 Leukemia, Lymphocytic, Chronic, B-Cell trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Lymphocytic, Chronic, B-Cell Phase: Phase 1 Country / region: China Clear all

27 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20151
20162
20171
20182
20193
20204
20215
20224
20233
20241
20251

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status12
Active, not recruiting4
Recruiting4
Completed3
Terminated2
Withdrawn2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Institute of Hematology & Blood Diseases Hospital, China2
Janssen Research & Development, LLC2
Shanghai YingLi Pharmaceutical Co. Ltd.2
Shenzhen Second People's Hospital2
The First Affiliated Hospital with Nanjing Medical University2
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology2
Ascentage Pharma Group Inc.1
BeOne Medicines1
Beijing Boren Hospital1
CytoCares Inc1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Lymphocytic, Chronic, B-Cell27
Lymphoma, B-Cell9
Lymphoma, Non-Hodgkin9
Precursor Cell Lymphoblastic Leukemia-Lymphoma7
Lymphoma, Mantle-Cell4
Lymphoma, B-Cell, Marginal Zone3
Lymphoma, Follicular3
Lymphoma, Large B-Cell, Diffuse3
Recurrence2
Anemia, Hemolytic, Autoimmune1

Trials

Showing 1 to 25 of 27. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.